M Saraheimo1, A-M Teppo, C Forsblom, J Fagerudd, P-H Groop. 1. Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, and Folkhälsan Research Centre, Bimedicum Helsinki, University of Helsinki, Finland.
Abstract
AIMS/HYPOTHESIS: Increased concentrations of C-reactive protein and interleukin-6, a finding suggestive of the presence of inflammation, have been observed in Type 2 diabetes. In such patients, C-reactive protein was predictive of diabetic nephropathy. Studies on low-grade inflammatory markers and nephropathy in Type 1 diabetic patients have shown conflicting results. Therefore we studied whether low-grade inflammation is associated with diabetic nephropathy in Type 1 diabetic patients. METHODS: We divided 194 Type 1 diabetic patients into three groups from the Finnish Diabetic Nephropathy Study based upon their albumin excretion rate. Patients with normoalbuminuria (n=67) had no antihypertensive medication or signs of cardiovascular disease, while patients with microalbuminuria (n=64) or macroalbuminuria (n=63) were all treated with an angiotensin-converting enzyme inhibitor, a drug that could attenuate low-grade inflammation. As a measure of insulin sensitivity we used estimated glucose disposal rate. C-reactive protein was measured by radioimmunoassay and interleukin-6 by high sensitivity enzyme immunoassay. RESULTS: C-reactive protein was higher in micro- and macroalbuminuric patients compared to normoalbuminuric patients (normoalbuminuria 2.0+/-1.7, microalbuminuria 2.6+/-1.7, macroalbuminuria 2.9+/-2.5 mg/l; p=0.016), while interleukin-6 increased in parallel with the severity of the renal disease (1.9+/-1.5, 2.9+/-3.3, 3.6+/-3.1 ng/l; p<0.0001). In multiple regression analysis albumin excretion rate was the only variable independently associated with C-reactive protein (p=0.03), whereas albumin excretion rate (p=0.0003), HDL-cholesterol (p=0.0135) and duration of diabetes (p=0.0176) were independently associated with interleukin-6. CONCLUSIONS/ INTERPRETATION: Low-grade inflammatory markers are associated with diabetic nephropathy in Type 1 diabetic patients. The predictive value needs to be assessed.
AIMS/HYPOTHESIS: Increased concentrations of C-reactive protein and interleukin-6, a finding suggestive of the presence of inflammation, have been observed in Type 2 diabetes. In such patients, C-reactive protein was predictive of diabetic nephropathy. Studies on low-grade inflammatory markers and nephropathy in Type 1 diabeticpatients have shown conflicting results. Therefore we studied whether low-grade inflammation is associated with diabetic nephropathy in Type 1 diabeticpatients. METHODS: We divided 194 Type 1 diabeticpatients into three groups from the Finnish Diabetic Nephropathy Study based upon their albumin excretion rate. Patients with normoalbuminuria (n=67) had no antihypertensive medication or signs of cardiovascular disease, while patients with microalbuminuria (n=64) or macroalbuminuria (n=63) were all treated with an angiotensin-converting enzyme inhibitor, a drug that could attenuate low-grade inflammation. As a measure of insulin sensitivity we used estimated glucose disposal rate. C-reactive protein was measured by radioimmunoassay and interleukin-6 by high sensitivity enzyme immunoassay. RESULTS:C-reactive protein was higher in micro- and macroalbuminuric patients compared to normoalbuminuric patients (normoalbuminuria 2.0+/-1.7, microalbuminuria 2.6+/-1.7, macroalbuminuria 2.9+/-2.5 mg/l; p=0.016), while interleukin-6 increased in parallel with the severity of the renal disease (1.9+/-1.5, 2.9+/-3.3, 3.6+/-3.1 ng/l; p<0.0001). In multiple regression analysis albumin excretion rate was the only variable independently associated with C-reactive protein (p=0.03), whereas albumin excretion rate (p=0.0003), HDL-cholesterol (p=0.0135) and duration of diabetes (p=0.0176) were independently associated with interleukin-6. CONCLUSIONS/ INTERPRETATION: Low-grade inflammatory markers are associated with diabetic nephropathy in Type 1 diabeticpatients. The predictive value needs to be assessed.
Authors: M Shikano; H Sobajima; H Yoshikawa; T Toba; H Kushimoto; H Katsumata; M Tomita; S Kawashima Journal: Nephron Date: 2000-05 Impact factor: 2.847
Authors: C G Schalkwijk; D C Poland; W van Dijk; A Kok; J J Emeis; A M Dräger; A Doni; V W van Hinsbergh; C D Stehouwer Journal: Diabetologia Date: 1999-03 Impact factor: 10.122
Authors: V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack Journal: J Clin Endocrinol Metab Date: 1997-12 Impact factor: 5.958
Authors: Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková Journal: Hum Gene Ther Date: 2012-01-26 Impact factor: 5.695
Authors: Ville-Petteri Mäkinen; Pasi Soininen; Carol Forsblom; Maija Parkkonen; Petri Ingman; Kimmo Kaski; Per-Henrik Groop; Mika Ala-Korpela Journal: MAGMA Date: 2006-12-15 Impact factor: 2.310
Authors: S Araki; M Haneda; D Koya; T Sugimoto; K Isshiki; M Chin-Kanasaki; T Uzu; A Kashiwagi Journal: Diabetologia Date: 2007-01-16 Impact factor: 10.122
Authors: M Saraheimo; C Forsblom; T K Hansen; A-M Teppo; J Fagerudd; K Pettersson-Fernholm; S Thiel; L Tarnow; P Ebeling; A Flyvbjerg; P-H Groop Journal: Diabetologia Date: 2004-12-23 Impact factor: 10.122
Authors: Johan Wadén; Heidi K Tikkanen; Carol Forsblom; Valma Harjutsalo; Lena M Thorn; Markku Saraheimo; Nina Tolonen; Milla Rosengård-Bärlund; Daniel Gordin; Heikki O Tikkanen; Per-Henrik Groop Journal: Diabetologia Date: 2015-01-30 Impact factor: 10.122
Authors: Mari A Kaunisto; Lisa Sjölind; Riitta Sallinen; Kim Pettersson-Fernholm; Markku Saraheimo; Sara Fröjdö; Carol Forsblom; Johan Fagerudd; Troels K Hansen; Allan Flyvbjerg; Maija Wessman; Per-Henrik Groop Journal: Diabetes Date: 2009-04-14 Impact factor: 9.461
Authors: Ervin R Fox; Emelia J Benjamin; Daniel F Sarpong; Harsha Nagarajarao; Jason K Taylor; Michael W Steffes; Abdullah K Salahudeen; Michael F Flessner; Ermeg L Akylbekova; Caroline S Fox; Robert J Garrison; Herman A Taylor Journal: BMC Nephrol Date: 2010-01-15 Impact factor: 2.388